To the Editor With great interest, we read the article by Eggermont et al1 investigating the association between immune-related adverse events (irAEs) and recurrence-free survival (RFS) in patients with melanoma undergoing adjuvant treatment with pembrolizumab in the EORTC 1325/KEYNOTE-054 study. The authors convincingly showed that the occurrence of irAEs was associated with increased RFS. Strikingly, although mild irAEs, such as vitiligo and endocrine irAEs, were strongly associated with RFS, there was no significant association with severe (grade 3 or greater) irAEs.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Suijkerbuijk KPM, Kapiteijn E, Verheijden RJ. Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors. JAMA Oncol. 2020;6(8):1300–1301. doi:10.1001/jamaoncol.2020.1932
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: